Skip to content

Study · Non-randomized trial · n = 30 · 2011

1 result

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.

Yan P, Li L, Yang M, Liu D, Liu H, Boden G, Yang G

Diabetes research and clinical practice31 Mar 2011Cited by 25 (Europe PMC)

PMID21458097 (opens in a new tab)DOI10.1016/j.diabres.2011.02.030 (opens in a new tab)PepBankPUB-21458097
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialMechanism

    In patients with type 2 diabetes, plasma omentin-1 rose significantly after 16 weeks of liraglutide compared with pre-treatment (19.3 versus 21.2 μg/L, P < 0.01).

    In plain wordsIn people with type 2 diabetes, plasma omentin-1 rose after 16 weeks of liraglutide compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    IncreasePlasma omentin-1 level after liraglutide
    Study

    n = 30

    Comparator
    Pre-treatment
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Plasma omentin-1 levels increased significantly in T2DM patients after treatment with liraglutide compared with pre-treatment (19.3 ± 4.0 μg/L vs. 21.2 ± 3. 9 μg/L, P < 0.01).
    1 context sentence
    Summary · context
    Thirty T2DM patients with poor glycemic control after more than 3 months of treatment with one or two OHA(s) (T2DM), and 30 matched normal glycaemic controls (NGT) participated in the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.